Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 435 entries
Sorted by: Best Match Show Resources per page
Performance of [.

Alzheimer's & dementia (Amsterdam, Netherlands)

Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Escovar YM, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Farrar G, Smith APL, Buckley CJ, Thal DR, Zanette M, Curtis C.
PMID: 28795133
Alzheimers Dement (Amst). 2017 Jul 01;9:25-34. doi: 10.1016/j.dadm.2017.06.001. eCollection 2017.

INTRODUCTION: Performance of the amyloid tracer [METHODS: After [RESULTS: By SoT, sensitivity and specificity of majority image interpretations were, respectively, 91.9% and 87.5% with "original CERAD," 90.8% and 90.0% with "modified CERAD," and 85.7% and 100% with the 2012...

Cite
Salloway S, Gamez JE, Singh U, et al. Performance of [. Alzheimers Dement (Amst). 2017;9:25-34doi: 10.1016/j.dadm.2017.06.001.
Salloway, S., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., Walker, Z., Hunjan, A., Escovar, Y. M., Agronin, M. E., Ross, J., Bozoki, A., Akinola, M., Shi, J., Vandenberghe, R., Ikonomovic, M. D., Sherwin, P. F., Farrar, G., Smith, A. P. L., Buckley, C. J., Thal, D. R., Zanette, M., & Curtis, C. (2017). Performance of [. Alzheimer's & dementia (Amsterdam, Netherlands), 925-34. https://doi.org/10.1016/j.dadm.2017.06.001
Salloway, Stephen, et al. "Performance of [." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 9 (2017): 25-34. doi: https://doi.org/10.1016/j.dadm.2017.06.001
Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Escovar YM, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Farrar G, Smith APL, Buckley CJ, Thal DR, Zanette M, Curtis C. Performance of [. Alzheimers Dement (Amst). 2017 Jul 01;9:25-34. doi: 10.1016/j.dadm.2017.06.001. eCollection 2017. PMID: 28795133; PMCID: PMC5536824.
Copy Download .nbib Format: NLM
Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts.

Frontiers in aging neuroscience

Lue LF, Sabbagh MN, Chiu MJ, Jing N, Snyder NL, Schmitz C, Guerra A, Belden CM, Chen TF, Yang CC, Yang SY, Walker DG, Chen K, Reiman EM.
PMID: 28790911
Front Aging Neurosci. 2017 Jul 24;9:226. doi: 10.3389/fnagi.2017.00226. eCollection 2017.

The utility of plasma amyloid beta (Aβ) and tau levels for the clinical diagnosis of Alzheimer's disease (AD) dementia has been controversial. The main objective of this study was to compare Aβ42 and tau levels measured by the ultra-sensitive...

Cite
Lue LF, Sabbagh MN, Chiu MJ, et al. Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts. Front Aging Neurosci. 2017;9:226doi: 10.3389/fnagi.2017.00226.
Lue, L. F., Sabbagh, M. N., Chiu, M. J., Jing, N., Snyder, N. L., Schmitz, C., Guerra, A., Belden, C. M., Chen, T. F., Yang, C. C., Yang, S. Y., Walker, D. G., Chen, K., & Reiman, E. M. (2017). Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts. Frontiers in aging neuroscience, 9226. https://doi.org/10.3389/fnagi.2017.00226
Lue, Lih-Fen, et al. "Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts." Frontiers in aging neuroscience vol. 9 (2017): 226. doi: https://doi.org/10.3389/fnagi.2017.00226
Lue LF, Sabbagh MN, Chiu MJ, Jing N, Snyder NL, Schmitz C, Guerra A, Belden CM, Chen TF, Yang CC, Yang SY, Walker DG, Chen K, Reiman EM. Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts. Front Aging Neurosci. 2017 Jul 24;9:226. doi: 10.3389/fnagi.2017.00226. eCollection 2017. PMID: 28790911; PMCID: PMC5522888.
Copy Download .nbib Format: NLM
Argon plasma coagulation in the management of symptomatic gastrointestinal angiodysplasia: experience in 69 consecutive patients.

La Tunisie medicale

Bizid S, Sabbah M, Ben Abdallah H, Haddad W, Bouali R, Abdelli N.
PMID: 26895122
Tunis Med. 2015 Oct;93(10):606-11.

BACKGROUND: Gastrointestinal angiodysplasias are associated with a high bleeding risk.AIM: to evaluate the efficiency of argon plasma electrocoagulation in the treatment of gastrointestinal angiodysplasia and to identify predictive factors of success of this technique.METHODS: Retrospective study of patients with...

Cite
Bizid S, Sabbah M, Ben Abdallah H, et al. Argon plasma coagulation in the management of symptomatic gastrointestinal angiodysplasia: experience in 69 consecutive patients. Tunis Med. 2015;93(10):606-11
Bizid, S., Sabbah, M., Ben Abdallah, H., Haddad, W., Bouali, R., & Abdelli, N. (2015). Argon plasma coagulation in the management of symptomatic gastrointestinal angiodysplasia: experience in 69 consecutive patients. La Tunisie medicale, 93(10), 606-11.
Bizid, Sondes, et al. "Argon plasma coagulation in the management of symptomatic gastrointestinal angiodysplasia: experience in 69 consecutive patients." La Tunisie medicale vol. 93,10 (2015): 606-11.
Bizid S, Sabbah M, Ben Abdallah H, Haddad W, Bouali R, Abdelli N. Argon plasma coagulation in the management of symptomatic gastrointestinal angiodysplasia: experience in 69 consecutive patients. Tunis Med. 2015 Oct;93(10):606-11. PMID: 26895122.
Copy Download .nbib Format: NLM
Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms.

Neurology and therapy

Keine D, Zelek M, Walker JQ, Sabbagh MN.
PMID: 30900186
Neurol Ther. 2019 Jun;8(1):79-94. doi: 10.1007/s40120-019-0131-6. Epub 2019 Mar 21.

INTRODUCTION: Polypharmacy is a growing problem in the United States. The use of multiple medications increases the likelihood that a patient will experience potential drug interactions and adverse drug reactions (ADRs). Those individuals with dementia or Alzheimer's disease (AD)...

Cite
Keine D, Zelek M, Walker JQ, et al. Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms. Neurol Ther. 2019;8(1):79-94doi: 10.1007/s40120-019-0131-6.
Keine, D., Zelek, M., Walker, J. Q., & Sabbagh, M. N. (2019). Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms. Neurology and therapy, 8(1), 79-94. https://doi.org/10.1007/s40120-019-0131-6
Keine, Dorothy, et al. "Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms." Neurology and therapy vol. 8,1 (2019): 79-94. doi: https://doi.org/10.1007/s40120-019-0131-6
Keine D, Zelek M, Walker JQ, Sabbagh MN. Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms. Neurol Ther. 2019 Jun;8(1):79-94. doi: 10.1007/s40120-019-0131-6. Epub 2019 Mar 21. PMID: 30900186; PMCID: PMC6534631.
Copy Download .nbib Format: NLM
Four-Year Follow-up of Increased Vertical Dimension of Occlusion using Resin Composites.

Journal of International Society of Preventive & Community Dentistry

Assaf C, Fahd JC, Sabbagh J.
PMID: 30430077
J Int Soc Prev Community Dent. 2018 Sep-Oct;8(5):469-474. doi: 10.4103/jispcd.JISPCD_233_18. Epub 2018 Oct 08.

The objectives of this case report were to treat a severe loss of the vertical dimension of occlusion with indirect composite and to evaluate the durability of the restorations. A 55-year-old male complains from severe wear of teeth, leading...

Cite
Assaf C, Fahd JC, Sabbagh J. Four-Year Follow-up of Increased Vertical Dimension of Occlusion using Resin Composites. J Int Soc Prev Community Dent. 2018;8(5):469-474doi: 10.4103/jispcd.JISPCD_233_18.
Assaf, C., Fahd, J. C., & Sabbagh, J. (2018). Four-Year Follow-up of Increased Vertical Dimension of Occlusion using Resin Composites. Journal of International Society of Preventive & Community Dentistry, 8(5), 469-474. https://doi.org/10.4103/jispcd.JISPCD_233_18
Assaf, Cendrella, et al. "Four-Year Follow-up of Increased Vertical Dimension of Occlusion using Resin Composites." Journal of International Society of Preventive & Community Dentistry vol. 8,5 (2018): 469-474. doi: https://doi.org/10.4103/jispcd.JISPCD_233_18
Assaf C, Fahd JC, Sabbagh J. Four-Year Follow-up of Increased Vertical Dimension of Occlusion using Resin Composites. J Int Soc Prev Community Dent. 2018 Sep-Oct;8(5):469-474. doi: 10.4103/jispcd.JISPCD_233_18. Epub 2018 Oct 08. PMID: 30430077; PMCID: PMC6187888.
Copy Download .nbib Format: NLM
Organocatalysed decarboxylative protonation process from Meldrum's acid: enantioselective synthesis of isoxazolidinones.

Chemical communications (Cambridge, England)

Tite T, Sabbah M, Levacher V, Brière JF.
PMID: 24178176
Chem Commun (Camb). 2013 Dec 21;49(98):11569-71. doi: 10.1039/c3cc47695b.

An asymmetric organocatalysed decarboxylative protonation reaction allowed a straightforward synthesis of α-substituted isoxazolidin-5-ones from readily available 5-substituted Meldrum's acids. This process is initiated by an anionic formal (3+2) cycloaddition-fragmentation, generated in-situ from a sulfone-amide precursor which also served as...

Cite
Tite T, Sabbah M, Levacher V, et al. Organocatalysed decarboxylative protonation process from Meldrum's acid: enantioselective synthesis of isoxazolidinones. Chem Commun (Camb). 2013;49(98):11569-71doi: 10.1039/c3cc47695b.
Tite, T., Sabbah, M., Levacher, V., & Brière, J. F. (2013). Organocatalysed decarboxylative protonation process from Meldrum's acid: enantioselective synthesis of isoxazolidinones. Chemical communications (Cambridge, England), 49(98), 11569-71. https://doi.org/10.1039/c3cc47695b
Tite, Tony, et al. "Organocatalysed decarboxylative protonation process from Meldrum's acid: enantioselective synthesis of isoxazolidinones." Chemical communications (Cambridge, England) vol. 49,98 (2013): 11569-71. doi: https://doi.org/10.1039/c3cc47695b
Tite T, Sabbah M, Levacher V, Brière JF. Organocatalysed decarboxylative protonation process from Meldrum's acid: enantioselective synthesis of isoxazolidinones. Chem Commun (Camb). 2013 Dec 21;49(98):11569-71. doi: 10.1039/c3cc47695b. PMID: 24178176.
Copy Download .nbib Format: NLM
Is Adjuvant Chemotherapy Necessary for Obstructing Stage II Colon Cancer? Results From a Propensity Score Analysis of the French Surgical Association Database.

Annals of surgery

Sabbagh C, Manceau G, Mege D, Abdalla S, Voron T, Bridoux V, Lakkis Z, Venara A, Beyer-Berjot L, Diouf M, Karoui M.
PMID: 32068553
Ann Surg. 2020 Feb 14; doi: 10.1097/SLA.0000000000003832. Epub 2020 Feb 14.

OBJECTIVE: The aim of this study was to compare the survival of patients with stage II obstructing colon cancer (OCC) who had adjuvant chemotherapy with those who did not.SUMMARY BACKGROUND DATA: The need for adjuvant chemotherapy in stage II...

Cite
Sabbagh C, Manceau G, Mege D, et al. Is Adjuvant Chemotherapy Necessary for Obstructing Stage II Colon Cancer? Results From a Propensity Score Analysis of the French Surgical Association Database. Ann Surg. 2020;doi: 10.1097/SLA.0000000000003832.
Sabbagh, C., Manceau, G., Mege, D., Abdalla, S., Voron, T., Bridoux, V., Lakkis, Z., Venara, A., Beyer-Berjot, L., Diouf, M., Karoui, M. (2020). Is Adjuvant Chemotherapy Necessary for Obstructing Stage II Colon Cancer? Results From a Propensity Score Analysis of the French Surgical Association Database. Annals of surgery, . https://doi.org/10.1097/SLA.0000000000003832
Sabbagh, Charles, et al. "Is Adjuvant Chemotherapy Necessary for Obstructing Stage II Colon Cancer? Results From a Propensity Score Analysis of the French Surgical Association Database." Annals of surgery vol. (2020). doi: https://doi.org/10.1097/SLA.0000000000003832
Sabbagh C, Manceau G, Mege D, Abdalla S, Voron T, Bridoux V, Lakkis Z, Venara A, Beyer-Berjot L, Diouf M, Karoui M. Is Adjuvant Chemotherapy Necessary for Obstructing Stage II Colon Cancer? Results From a Propensity Score Analysis of the French Surgical Association Database. Ann Surg. 2020 Feb 14; doi: 10.1097/SLA.0000000000003832. Epub 2020 Feb 14. PMID: 32068553.
Copy Download .nbib Format: NLM
Mesenchymal Stromal Cells Accelerate Epithelial Tight Junction Assembly via the AMP-Activated Protein Kinase Pathway, Independently of Liver Kinase B1.

Stem cells international

Rowart P, Erpicum P, Krzesinski JM, Sebbagh M, Jouret F.
PMID: 28781597
Stem Cells Int. 2017;2017:9717353. doi: 10.1155/2017/9717353. Epub 2017 Jul 11.

BACKGROUND: Mesenchymal stromal cells (MSC) are fibroblast-like multipotent cells capable of tissue-repair properties. Given the essentiality of tight junctions (TJ) in epithelial integrity, we hypothesized that MSC modulate TJ formation, via the AMP-activated kinase (AMPK) pathway. Liver kinase-METHODS: The...

Cite
Rowart P, Erpicum P, Krzesinski JM, et al. Mesenchymal Stromal Cells Accelerate Epithelial Tight Junction Assembly via the AMP-Activated Protein Kinase Pathway, Independently of Liver Kinase B1. Stem Cells Int. 2017;2017:9717353doi: 10.1155/2017/9717353.
Rowart, P., Erpicum, P., Krzesinski, J. M., Sebbagh, M., & Jouret, F. (2017). Mesenchymal Stromal Cells Accelerate Epithelial Tight Junction Assembly via the AMP-Activated Protein Kinase Pathway, Independently of Liver Kinase B1. Stem cells international, 20179717353. https://doi.org/10.1155/2017/9717353
Rowart, P, et al. "Mesenchymal Stromal Cells Accelerate Epithelial Tight Junction Assembly via the AMP-Activated Protein Kinase Pathway, Independently of Liver Kinase B1." Stem cells international vol. 2017 (2017): 9717353. doi: https://doi.org/10.1155/2017/9717353
Rowart P, Erpicum P, Krzesinski JM, Sebbagh M, Jouret F. Mesenchymal Stromal Cells Accelerate Epithelial Tight Junction Assembly via the AMP-Activated Protein Kinase Pathway, Independently of Liver Kinase B1. Stem Cells Int. 2017;2017:9717353. doi: 10.1155/2017/9717353. Epub 2017 Jul 11. PMID: 28781597; PMCID: PMC5525096.
Copy Download .nbib Format: NLM
Biological scoring system for early prediction of acute bowel ischemia after cardiac surgery: the PALM score.

Annals of intensive care

Zogheib E, Cosse C, Sabbagh C, Marx S, Caus T, Henry M, Nader J, Fumery M, Bernasinski M, Besserve P, Trojette F, Renard C, Duhaut P, Kamel S, Regimbeau JM, Dupont H.
PMID: 29671149
Ann Intensive Care. 2018 Apr 18;8(1):46. doi: 10.1186/s13613-018-0395-5.

BACKGROUND: Bowel ischemia is a life-threatening emergency defined as an inadequate vascular perfusion leading to bowel inflammation resulting from impaired colonic/small bowel blood supply. Main issue for physicians regarding bowel ischemia diagnosis lies in the absence of informative and...

Cite
Zogheib E, Cosse C, Sabbagh C, et al. Biological scoring system for early prediction of acute bowel ischemia after cardiac surgery: the PALM score. Ann Intensive Care. 2018;8(1):46doi: 10.1186/s13613-018-0395-5.
Zogheib, E., Cosse, C., Sabbagh, C., Marx, S., Caus, T., Henry, M., Nader, J., Fumery, M., Bernasinski, M., Besserve, P., Trojette, F., Renard, C., Duhaut, P., Kamel, S., Regimbeau, J. M., & Dupont, H. (2018). Biological scoring system for early prediction of acute bowel ischemia after cardiac surgery: the PALM score. Annals of intensive care, 8(1), 46. https://doi.org/10.1186/s13613-018-0395-5
Zogheib, Elie, et al. "Biological scoring system for early prediction of acute bowel ischemia after cardiac surgery: the PALM score." Annals of intensive care vol. 8,1 (2018): 46. doi: https://doi.org/10.1186/s13613-018-0395-5
Zogheib E, Cosse C, Sabbagh C, Marx S, Caus T, Henry M, Nader J, Fumery M, Bernasinski M, Besserve P, Trojette F, Renard C, Duhaut P, Kamel S, Regimbeau JM, Dupont H. Biological scoring system for early prediction of acute bowel ischemia after cardiac surgery: the PALM score. Ann Intensive Care. 2018 Apr 18;8(1):46. doi: 10.1186/s13613-018-0395-5. PMID: 29671149; PMCID: PMC5906418.
Copy Download .nbib Format: NLM
The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis.

Cancers

Delangle R, De Foucher T, Larsen AK, Sabbah M, Azaïs H, Bendifallah S, Daraï E, Ballester M, Mehats C, Uzan C, Canlorbe G.
PMID: 31208108
Cancers (Basel). 2019 Jun 16;11(6). doi: 10.3390/cancers11060832.

No abstract available.

Cite
Delangle R, De Foucher T, Larsen AK, et al. The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis. Cancers (Basel). 2019;11(6)doi: 10.3390/cancers11060832.
Delangle, R., De Foucher, T., Larsen, A. K., Sabbah, M., Azaïs, H., Bendifallah, S., Daraï, E., Ballester, M., Mehats, C., Uzan, C., & Canlorbe, G. (2019). The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis. Cancers, 11(6), . https://doi.org/10.3390/cancers11060832
Delangle, Romain, et al. "The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis." Cancers vol. 11,6 (2019). doi: https://doi.org/10.3390/cancers11060832
Delangle R, De Foucher T, Larsen AK, Sabbah M, Azaïs H, Bendifallah S, Daraï E, Ballester M, Mehats C, Uzan C, Canlorbe G. The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis. Cancers (Basel). 2019 Jun 16;11(6). doi: 10.3390/cancers11060832. PMID: 31208108; PMCID: PMC6628044.
Copy Download .nbib Format: NLM
Residual Tumor Confers a 10-Fold Increased Risk of Regrowth in Clinically Nonfunctioning Pituitary Tumors.

Journal of the Endocrine Society

Maletkovic J, Dabbagh A, Zhang D, Zahid A, Bergsneider M, Wang MB, Linetsky M, Salamon N, Yong WH, Vinters HV, Heaney AP.
PMID: 31598573
J Endocr Soc. 2019 Jul 23;3(10):1931-1941. doi: 10.1210/js.2019-00163. eCollection 2019 Oct 01.

OBJECTIVE: We evaluated tumor recurrence and regrowth rates following endoscopic transnasal transsphenoidal (TNTS) surgical removal in a consecutive series of clinically nonfunctioning pituitary adenomas (CNFTs).DESIGN: Retrospective chart review of clinical, biochemical, and sellar MRI findings in all TNTS surgeries...

Cite
Maletkovic J, Dabbagh A, Zhang D, et al. Residual Tumor Confers a 10-Fold Increased Risk of Regrowth in Clinically Nonfunctioning Pituitary Tumors. J Endocr Soc. 2019;3(10):1931-1941doi: 10.1210/js.2019-00163.
Maletkovic, J., Dabbagh, A., Zhang, D., Zahid, A., Bergsneider, M., Wang, M. B., Linetsky, M., Salamon, N., Yong, W. H., Vinters, H. V., & Heaney, A. P. (2019). Residual Tumor Confers a 10-Fold Increased Risk of Regrowth in Clinically Nonfunctioning Pituitary Tumors. Journal of the Endocrine Society, 3(10), 1931-1941. https://doi.org/10.1210/js.2019-00163
Maletkovic, Jelena, et al. "Residual Tumor Confers a 10-Fold Increased Risk of Regrowth in Clinically Nonfunctioning Pituitary Tumors." Journal of the Endocrine Society vol. 3,10 (2019): 1931-1941. doi: https://doi.org/10.1210/js.2019-00163
Maletkovic J, Dabbagh A, Zhang D, Zahid A, Bergsneider M, Wang MB, Linetsky M, Salamon N, Yong WH, Vinters HV, Heaney AP. Residual Tumor Confers a 10-Fold Increased Risk of Regrowth in Clinically Nonfunctioning Pituitary Tumors. J Endocr Soc. 2019 Jul 23;3(10):1931-1941. doi: 10.1210/js.2019-00163. eCollection 2019 Oct 01. PMID: 31598573; PMCID: PMC6777402.
Copy Download .nbib Format: NLM
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M.
PMID: 29877179
Can Urol Assoc J. 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187.

INTRODUCTION: The Kidney Cancer Research Network of Canada (KCRNC) collaborated to prepare this consensus statement about the use of target agents as adjuvant therapy in patients with non-metastatic renal cell carcinoma (nmRCC) after nephrectomy. We reviewed the published data...

Cite
Karakiewicz PI, Zaffuto E, Kapoor A, et al. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Can Urol Assoc J. 2018;12(6):173-180doi: 10.5489/cuaj.5187.
Karakiewicz, P. I., Zaffuto, E., Kapoor, A., Basappa, N. S., Bjarnason, G. A., Blais, N., Breau, R. H., Canil, C., Drachenberg, D., Hotte, S. J., Jeldres, C., Jewett, M. A. S., Kassouf, W., Kollmannsberger, C., Lavallée, L. T., Maloni, R., Patenaude, F., Pouliot, F., Reaume, M. N., Sabbagh, R., Shayegan, B., So, A., Soulières, D., Tanguay, S., Wood, L., & Bandini, M. (2018). Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 12(6), 173-180. https://doi.org/10.5489/cuaj.5187
Karakiewicz, Pierre I, et al. "Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 12,6 (2018): 173-180. doi: https://doi.org/10.5489/cuaj.5187
Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Can Urol Assoc J. 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187. PMID: 29877179; PMCID: PMC5994982.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 435 entries